Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Approves Financials with KRW 4.16T Revenue and Confirms KRW 750 Cash Dividend per Common Share at AGM

Posted on March 24, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Approves Financials with KRW 4.16T Revenue and Confirms KRW 750 Cash Dividend per Common Share at AGM

Fact Source: Financial Supervisory Service DART / 2026-03-24

Disclosure Type: Results of Annual General Meeting of Shareholders

💡 3-Second Summary

Celltrion held its Annual General Meeting (AGM) where shareholders officially approved consolidated financial statements featuring KRW 4.16 trillion in revenue, while confirming a final cash dividend of KRW 750 per common share (totaling approximately KRW 164 billion).

📊 1. [Summary of Key Disclosure Content and Major Figures]

  • AGM Date: March 24, 2026
  • Record Date for Voting Rights: December 31, 2025

[Approval of Financial Statements (35th Fiscal Year, Consolidated)]

  • Total Assets: KRW 22,334,900 million (Approx. KRW 22.33T)
  • Total Liabilities: KRW 4,982,370 million (Approx. KRW 4.98T)
  • Total Equity: KRW 17,352,530 million (Approx. KRW 17.35T) / Share Capital: KRW 239,362 million (Approx. KRW 239.3B)
  • Revenue: KRW 4,162,495 million (Approx. KRW 4.16T)
  • Operating Profit: KRW 1,168,471 million (Approx. KRW 1.16T)
  • Net Income: KRW 1,031,484 million (Approx. KRW 1.03T)
  • Earnings Per Share (EPS): KRW 4,668
  • External Auditor’s Opinion: Unqualified (“Appropriate”) for both consolidated and separate statements

[Dividend Resolution Details]

  • Dividend Type: Cash Dividend (Final dividend of KRW 750 per common share)
  • Total Dividend Amount: KRW 163,959,843,000 (Approx. KRW 164B)
  • Dividend Yield: 0.4% for common shares (based on the arithmetic average closing price of the week preceding the board resolution date of December 11, 2025)

[Key AGM Agenda & Executive Appointments]

  • All proposed agendas, including the approval of financial statements, articles of incorporation amendments (related to cumulative voting, the board of directors, and treasury share disposition), and director compensation limits, were officially approved.
  • Inside Directors: Ki Woo-sung (re-appointed), Shin Min-chul (newly appointed)
  • Outside Directors & Audit Committee Members: Koh Young-hye, Choi Won-kyung, Choe Jong-moon, Lee Joong-jae (all re-appointed), Yoon Tae-wha (newly appointed)
  • Cumulative Voting: Resolution approved to amend articles to remove the exclusion of cumulative voting, aligning with Commercial Act revisions. This will apply to shareholder meetings held on or after September 10, 2026, where directors are nominated.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

The AGM results reinforce Celltrion’s fundamental stability by formalizing robust top-line and bottom-line metrics into legally approved financial statements. Achieving consolidated revenues of approximately KRW 4.16T and operating profit of KRW 1.16T, backed by an unqualified auditor’s opinion, provides a transparent foundation for the business.

Crucially, the approval of the KRW 750 per share cash dividend (KRW 164 billion in total) secures immediate cash inflows for shareholders. Although the dividend yield of 0.4% is modest, when coupled with the previously announced capital actions—such as the massive treasury stock cancellation—it could be interpreted as a potential positive driver for total shareholder return.

Additionally, removing the cumulative voting exclusion clause marks a meaningful shift in governance (ESG). While this could eventually empower minority shareholders, its practical impact on board structures may only become clear during director elections held after the September 10, 2026 effective date.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has officially locked in its record-scale performance of over KRW 4 trillion in revenue and KRW 1 trillion in operating profit through a smooth AGM passage. While the cash dividend yield is on the lower side, it represents a stable payout when viewed alongside the company’s aggressive share cancellation program. Furthermore, the governance reform to clear the way for cumulative voting signals a proactive step toward ESG standards. With the corporate charter updated and a refined board in place, the focus now turns to how efficiently Celltrion deploys its robust cash flows to secure its next high-growth avenues.

📢 Disclaimer and Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) Decides to Cancel 9.11 Million Treasury Shares Valued at Approx. KRW 1.72T for Shareholder Value Enhancement
Next Post: [Disclosure] AGM Results: Wonik IPS (240810) Approves KRW 909.8B Revenue & KRW 200 Cash Dividend; Veteran Kim Yong-kil Appointed Inside Director

Related Posts

[Disclosure] Celltrion 068270 Revises Q3 Provisional Operating Profit Upward to KRW 301.4B… Surging 45.13% YoY Disclosures
[Disclosure] Celltrion (068270) Signs Final Contract to Acquire U.S. API Facility Holder ‘Imclone Systems’ for KRW 460B (USD 330M) Disclosures
[Disclosure] SK square(402340), Subsidiary SK hynix Confirms Nasdaq Listing and KRW 40T ADR Issuance Terms Disclosures
[Disclosure] Celltrion (068270) Decides to Dispose of 11,379 Treasury Shares Worth KRW 1.65B for Stock Option Settlements Disclosures
[Disclosure] Alteogen(196170) Lifted from ‘Investment Warning’ Status; Designated as ‘Investment Caution’ Stock with Re-designation Warning on March 18 Disclosures
[Disclosure] Samsung Biologics (207940) Reports Q4 2025 Preliminary Revenue of KRW 1.29T and Operating Profit of KRW 528.3B… Up 67.8% YoY Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme